ClinicalTrials.gg
Not yet recruitingNCT07829575Updated Sep 21, 2026

Amygdala-Targeted Transcranial Temporal Interference Stimulation for Major Depressive Disorder: A Randomized Sham-Controlled Trial of Clinical Efficacy and Neurobiological Mechanisms

An interventional study of Transcranial Temporal Interference Stimulation and Sham Transcranial Temporal Interference Stimulation in Major Depressive Disorder (MDD, sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Planned enrollment
128th of 174
60 · median 120
Started
2026
with 22 others
No phase
100 of 207
49 open now
Primary completion
2027-12
later than 59 of 76 live
Registered
203rd of 207
by date

Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 128th largest by planned enrollment of the 174 interventional ones that give a count, is one of 23 that started in 2026, is one of 100 with no phase, reaches primary completion later than 59 of the 76 other live ones, and was the 203rd registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

This randomized, sham-controlled clinical trial aims to evaluate the efficacy and safety of amygdala-targeted transcranial temporal interference stimulation (tTIS) in adults with major depressive disorder (MDD) and to explore its potential neurobiological mechanisms.

The main questions this study aims to answer are:

Whether active amygdala-targeted tTIS reduces depressive symptoms compared with sham stimulation.

Whether tTIS produces changes in amygdala-related neural activity and functional brain networks that are associated with clinical improvement.

Participants will be randomly assigned to receive either active tTIS or sham stimulation. They will complete a course of stimulation sessions and undergo clinical assessments before and after the intervention. Neuroimaging assessments will also be performed to investigate treatment-related changes in the amygdala and associated brain networks.

03

Conditions studied

  • Major Depressive Disorder (MDD

Keywords

  • Transcranial Temporal Interference Stimulation
  • Major Depressive Disorde
  • Amygdala
  • Neuromodulation
  • Neuroimaging
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 55 years, inclusive, with no restriction on sex.
  2. Diagnosed with Major Depressive Disorder (MDD) according to the , Fifth Edition (DSM-5), as determined by a study physician.
  3. A 17-item Hamilton Depression Rating Scale (HAMD-17) score ≥17 at screening/baseline.
  4. The antidepressant medication regimen must remain stable from at least 30 days before signing the form through the study period.
  5. In the judgment of the investigator, the participant or their legally authorized representative is able to understand the purpose and procedures of the study, comply with the study protocol, and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. A history of other psychiatric disorders, neurological disorders, or substance abuse that, in the investigator's judgment, may interfere with the assessment of treatment efficacy.
  2. A history of epilepsy, seizures, or convulsive episodes.
  3. Presence of intracranial metallic foreign bodies or metallic implants in or near the heart.
  4. Presence of organic brain disease, or a history of severe head injury or cranial surgery.
  5. Receipt of electroconvulsive therapy (ECT) or other physical treatments, such as transcranial magnetic stimulation (TMS), within the 30 days before enrollment.
  6. An unstable psychiatric condition or significant suicide risk, as assessed by the investigator.
  7. Women who are pregnant or breastfeeding.
  8. Current participation in another interventional clinical trial.
  9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active tTIS

    Device: Transcranial Temporal Interference Stimulation

  • Sham comparator
    Sham tTIS

    Device: Sham Transcranial Temporal Interference Stimulation

Interventions

  • DeviceTranscranial Temporal Interference Stimulation

    Active transcranial temporal interference stimulation (tTIS) will be delivered using two pairs of scalp electrodes. Two high-frequency alternating currents with slightly different carrier frequencies will be applied to generate a low-frequency temporal interference envelope within the targeted amygdala region. Electrode placement and stimulation parameters will be determined according to the study protocol and individualized electric-field modeling when applicable. Participants assigned to the active group will receive 10 stimulation sessions, with each session lasting 30 minutes, according to the predefined treatment schedule.

  • DeviceSham Transcranial Temporal Interference Stimulation

    Participants assigned to the sham group will undergo the same electrode placement and treatment procedures as the active stimulation group. Sham stimulation will include brief ramp-up and ramp-down periods to mimic the initial sensory experience of active stimulation, without delivering continuous therapeutic stimulation during the remainder of the session.

06

What researchers measure

Primary outcomes

  1. Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score

    The 17-item Hamilton Depression Rating Scale (HAMD-17) is a clinician-rated scale used to assess the severity of depressive symptoms. Total scores range from 0 to 52, with higher scores indicating greater depressive symptom severity. The primary outcome is the change in HAMD-17 total score from baseline to the end of the 10-session intervention.

    Time frame: Baseline; after 10 stimulation sessions (30 minutes per session; end of Week 2)

Secondary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated scale used to assess the severity of depressive symptoms. Total scores range from 0 to 60, with higher scores indicating greater depressive symptom severity. Changes in MADRS total score from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  2. Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score Across Treatment and Follow-up

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  3. Change in Hamilton Anxiety Rating Scale (HAMA) Total Score

    The Hamilton Anxiety Rating Scale (HAMA) is a clinician-rated scale used to assess the severity of anxiety symptoms. Total scores range from 0 to 56, with higher scores indicating greater anxiety severity. Changes in HAMA total score from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  4. Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score

    The Snaith-Hamilton Pleasure Scale (SHAPS) is used to assess anhedonia and reduced capacity to experience pleasure. Changes in SHAPS score from baseline will be used to evaluate treatment-related changes in hedonic functioning.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  5. Change in Pittsburgh Sleep Quality Index (PSQI) Global Score

    The Pittsburgh Sleep Quality Index (PSQI) is a self-reported measure of sleep quality and sleep disturbances. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Changes in PSQI global score from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  6. Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) Domain Scores

    The WHOQOL-BREF is a self-reported measure of quality of life across physical health, psychological health, social relationships, and environmental domains. Higher domain scores indicate better perceived quality of life. Changes in domain scores from baseline will be assessed after treatment and during follow-up.

    Time frame: Baseline,after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  7. Change in Generalized Anxiety Disorder-7 (GAD-7) Score

    The Generalized Anxiety Disorder-7 (GAD-7) is a self-reported measure of anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Changes in GAD-7 score from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  8. Change in Patient Health Questionnaire-9 (PHQ-9) Total Score

    The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-reported measure used to assess the severity of depressive symptoms. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Changes in PHQ-9 total score from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 1 week and 4 weeks after completion of the 10-session intervention.

  9. Change in Cognitive Performance Assessed by the THINC-integrated Tool (THINC-it)

    The THINC-integrated Tool (THINC-it) is a computerized cognitive assessment designed to evaluate subjective and objective cognitive functioning, including attention, processing speed, working memory, and executive function. Changes in THINC-it performance from baseline will be assessed following treatment and during follow-up.

    Time frame: Baseline,after 5 stimulation sessions (30 minutes per session; end of Week 1); after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  10. Change in Temporal Experience of Pleasure Scale (TEPS) Score

    The Temporal Experience of Pleasure Scale (TEPS) is a self-reported measure of anticipatory and consummatory pleasure. Changes in TEPS scores from baseline will be explored to assess treatment-related changes in reward-related emotional experience.

    Time frame: Baseline,after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  11. Change in Emotion Regulation Questionnaire (ERQ) Score

    The Emotion Regulation Questionnaire (ERQ) assesses habitual use of cognitive reappraisal and expressive suppression as emotion regulation strategies. Changes in ERQ scores from baseline will be explored following treatment and during follow-up.

    Time frame: Baseline,after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

Other outcomes

  1. DTI

    Diffusion tensor imaging (DTI) will be used to explore treatment-related changes in white matter microstructural measures within neural pathways associated with the amygdala and emotion-regulation networks.

    Time frame: Baseline,after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  2. fMRI

    Functional magnetic resonance imaging (fMRI) will be used to assess treatment-related changes in functional connectivity involving the amygdala and brain regions associated with emotional processing and regulation. Amygdala-based functional connectivity measures will be compared across study time points.

    Time frame: Baseline,after 10 stimulation sessions (30 minutes per session; end of Week 2); and at 4 weeks after completion of the 10-session intervention.

  3. Incidence of Treatment-Emergent Adverse Events

    Time frame: From the first stimulation session through the 4-week follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 14 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 21, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07829575
Lead sponsor
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Responsible party
Jingjing Huang, MD (Chief Physician, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University) — Principal investigator
First posted
Sep 21, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Jingjing Huang
Contact
huangjingjing18@tongji.edu.cn
021-68306699*1222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion